Chris Duignan, who has been named Chief Financial Officer of Flourish Research, will build the financial infrastructure, lead financial operations, and integrate the acquisitions of the rapidly growing organization.
NEW YORK, Nov. 8, 2022 /PRNewswire-PRWeb/ -- Chris Duignan has been named Chief Financial Officer of Flourish Research, a diversified clinical trial company designed to acquire, operate, and integrate large, best-in-class clinical research sites with expertise in studies spanning Phases I-IV.
Mr. Duignan will build the financial infrastructure, lead financial operations, and integrate the acquisitions of the rapidly growing organization. He is a highly experienced senior financial executive with more than 25 years of public and private company experience, including 14 years in the life sciences industry.
Mr. Duignan was most recently a VP of Finance at an independent clinical research network comprised of 21 wholly owned clinical sites. Chris previously spent six years as the VP of Finance at the New York Genome Center, building the financial architecture of the DNA sequencing center.
"Chris brings with him a deep understanding of our industry and the ability to leverage financial management and reporting to help research sites thrive," said Reinhold Schulz, Chief Executive Officer of Flourish. "We are fortunate to have him on the leadership team to guide us during our time of expansion."
Chris Duignan stated, "I'm excited to join the Flourish team and work with top-notch, seasoned pharmaceutical services professionals during this time of company-wide growth."
Mr. Duignan spent the first four years of his career at PricewaterhouseCoopers, holds a Bachelor of Science in Accounting from Fairfield University, and spent six years in the Marine Corps Reserves.
About Flourish Research:
Flourish Research is a leading clinical trial organization, created to strategically acquire, create, and operate the best clinical trial sites in North America. Flourish sites started as some of the most recognized trial sites in the industry including Clinical Trials of Texas, Excel Medical Clinical Trials, Clinical Sites Partners, Keystone Clinical, and Great Lakes Clinical Trials.
Flourish sites conduct Phase I-IV studies across therapeutic areas where they have deep expertise, including Cardiology/Metabolic Disease/Renal, CNS, Pulmonology and Vaccines. Flourish key investigators are full-time, dedicated to research at sites that are large and highly experienced.
Media Contact
Cindi Heckmann, Flourish Research, 1 210-854-1614, [email protected]
SOURCE Flourish Research
Share this article